Research Study Findings from Research Center for Hematology Update Understanding of Chronic Myelogenous Leukemia (The case of successful therapy with Nilotinib in patients with Ph-positive chronic myelogenous leukemia of chronic phase resistant...).

Keywords: Antineoplastics; BCR-ABL Tyrosine Kinase Inhibitors; Cancer; Chronic Myelogenous Leukemia; Cytokines; Drugs and Therapies; Gleevec Therapy; Health and Medicine; Hematology; Imatinib Mesylate; Intercellular Signaling Peptides and Proteins; Interferons; Leukemia; Myelogenous Leukemia; Nilotinib; Nilotinib Therapy; Oncology; Pharmaceuticals; Tyrosine Kinase Inhibitors EN Antineoplastics BCR-ABL Tyrosine Kinase Inhibitors Cancer Chronic Myelogenous Leukemia Cytokines Drugs and Therapies Gleevec Therapy Health and Medicine Hematology Imatinib Mesylate Intercellular Signaling Peptides and Proteins Interferons Leukemia Myelogenous Leukemia Nilotinib Nilotinib Therapy Oncology Pharmaceuticals Tyrosine Kinase Inhibitors 864 864 1 04/17/23 20230421 NES 230421 2023 APR 17 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- New study results on chronic myelogenous leukemia have been published. For more information on this research see: The case of successful therapy with Nilotinib in patients with Ph-positive chronic myelogenous leukemia of chronic phase resistant to Interferon and Gleevec. [Extracted from the article]